Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Efficacy and Tolerance of Azacitidine (AZA) In MDS-associated Steroid Dependent/Refractory Systemic Auto-immune and Inflammatory Disorders (SAID)

NCT02985190 is registered in ClinicalTrials.gov with Groupe Francophone des Myelodysplasies as lead sponsor.

NCT NCT02985190
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02985190 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Efficacy and Tolerance of Azacitidine (AZA) In MDS-associated Steroid Dependent/Refractory Systemic Auto-immune and Inflammatory Disorders (SAID)
Lead sponsor
Groupe Francophone des Myelodysplasies
Phase
Phase 2
Overall status
Completed
Start date
January 26, 2017
Completion date
August 30, 2022
Enrollment
30 (actual)
Sites
59

Conditions

As the registry lists them; a condition with its own page is linked.

mds, systemic autoimmune diseases